Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$3.18 ▲ +0.00
(0.00%)
MKT CAP: $104.1M • VOL: 111.9K
52W L $2 52W H $9
ROARABLE / RQD
E • 27/100
PIOTROSKI
4 / 9
IMDX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.1M | $1.9M | $1.5M |
| YoY Revenue Growth % | +115.6% | +25.1% | — |
| Gross Profit | $2.3M | $740.0K | — |
| Gross Margin % | 56.7% | 39.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$51.1M | -$61.0M | -$25.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$50.2K | -$60.7K | -$27.8K |
| EBITDA (Normalized) | -$48.6M | -$60.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$22.2M | -$20.7M | -$23.3M |
| Capital Expenditures (CapEx) | $3.2M | $516.0K | — |
| Free Cash Flow (FCF) | -$25.4M | -$21.2M | -$23.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $11.6M | $8.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$31.5M | -$12.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMDX.